Cero Therapeutics Holdings, Inc.
CEROWFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Cero Therapeutics Holdings, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Apr 21, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-12-13 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −2,998,908 | 0.06 | SEC filing |
| 2024-12-12 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −1,614,541 | 0.07 | SEC filing |
| 2024-12-11 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −1,343,801 | 0.08 | SEC filing |
| 2024-12-10 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −1,570,947 | 0.09 | SEC filing |
| 2024-12-09 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −850,543 | 0.11 | SEC filing |
| 2024-12-06 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −1,236,874 | 0.12 | SEC filing |
| 2024-10-10 | YK Bioventures Opportunities GP I, LLC · 10% owner | Common Stock | S — Open market or private sale | −3,250,000 | 0.10 | SEC filing |
| 2024-09-25 | SLOAN STUART M · 10% owner | Common Stock, $0.0001 par value per share | S — Open market or private sale | −532,486 | 0.10 | SEC filing |
Showing 8 of 8 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-04 | Francois Eric · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,823,278 | SEC filing |
| 2026-01-07 | Byrnes Michael · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +690,900 | SEC filing |
| 2026-01-07 | ATWOOD BRIAN G · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,612,099 | SEC filing |
| 2026-01-07 | Ehrlich Christopher B · Chairman and CEO | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +4,530,997 | SEC filing |
| 2026-01-07 | Rolfe Lindsey · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +690,900 | SEC filing |
| 2026-01-07 | KUCHARCHUK ANDREW ALBERT · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,162,099 | SEC filing |
| 2026-01-07 | LAPORTE KATHLEEN · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +690,900 | SEC filing |
| 2026-01-07 | Pierce Kristen · Chief Development Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,612,099 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-09-30 | ATWOOD BRIAN G · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −13,857 | SEC filing |
| 2024-09-30 | ATWOOD BRIAN G · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −1,317,956 | SEC filing |
| 2024-09-30 | Ehrlich Christopher B · Interim Chairman and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −572,182 | SEC filing |
| 2024-02-14 | Fisher Douglas Carl · President | Warrants | J — Other acquisition or disposition | +5,000 | SEC filing |
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC · 10% owner | Common Stock | J — Other acquisition or disposition | −1,125,000 | SEC filing |
| 2024-02-14 | Ehrlich Christopher B · Director | Common Stock | J — Other acquisition or disposition | +3,600 | SEC filing |
| 2024-02-14 | Fisher Douglas Carl · President | Class A Common Stock | J — Other acquisition or disposition | +43,300 | SEC filing |
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | −1,555 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.